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Abstract 
We describe the case of a 14-year-old Caucasian male, a resident in the Democratic Republic of the Congo, who was observed in Portugal 
with severe Plasmodium falciparum malaria with high-level parasitemia and severe thrombocytopenia. The course was complicated by 
bilateral sixth cranial nerve palsy during acute malaria, followed by the appearance of delayed cerebellar ataxia during the recovery phase. 
This occurred after successful treatment with quinine plus doxycycline over seven days. Different levels of thrombocytopenia and C-reactive 
protein were observed during both neurologic events in the presence of HRP-2 positive tests for Plasmodium falciparum antigen. The patient 
recovered completely after three months. 
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Introduction 
Plasmodium falciparum malaria is the most 
common imported parasitic disease in Portugal. Most 
often patients are infected in Africa [1]. Malaria 
should be suspected in anyone with fever or history 
of fever who has returned from or previously visited 
a malaria endemic area, regardless of whether 
prophylaxis was taken or not. 
Typically, uncomplicated malaria presents as an 
undifferentiated febrile illness. However, several 
neurological complications are known. In 1994, in 
Vietnam, Nguyen described a post-malaria 
neurological syndrome (PMNS) in 1.8% of the 
patients after severe P. falciparum infection [2]. 
PMNS was defined in the presence of neurological or 
psychiatric symptoms within two months after 
recovery of acute illness. This implicates, in the case 
of symptomatic malaria infection with initial blood 
smear positive for asexual forms of the parasite, that 
parasites would have been cleared from the 
peripheral blood or, in the case of cerebral malaria, 
that the patient recovered complete consciousness 
[2]. Most cases described in the literature occurred in 
adults living in endemic areas for malaria, mainly in 
Asia and Africa, but additional cases were described 
in non-immune hosts (93%) who travelled to endemic 
countries without taking prophylaxis [3].  
Cerebellar involvement in P. falciparum malaria 
can occur during the acute stage of fever, as sequels 
of cerebral malaria in survivors, in the form of 
delayed cerebellar ataxia (DCA) and as a side effect 
of drugs [4]. Two syndromes of cerebellar ataxia 
have been recognized: acute (or early) cerebellar 
ataxia and delayed (or late) cerebellar ataxia [5,6]. 
Acute cerebellar ataxia has been described in 
patients with cerebral malaria who were found to 
have cerebellar ataxia on recovery from coma. 
Cerebral malaria was defined as asexual parasitemia 
in a febrile patient with an unrousable coma of more 
than six hours for which no other cause was evident 
[6]; it was also described in patients with acute 
malaria and P. falciparum positive asexual 
parasitemia after treatment with chloroquine [7]. 
DCA refers to patients who developed cerebellar 
ataxia shortly after full recovery from an 
uncomplicated attack of malaria [6]. 
DCA was first described in 1984 in residents and 
regular visitors to Sri Lanka [8]. Since then more 
cases have been described in Asia [9] and Africa [6], 
mainly in adults. Only a few cases have been reported 
to occur in children (<18 years) [5,6,9]. Here we 
describe a case of PMNS in a child, a resident in a P. 
falciparum endemic area, who developed DCA. It is 
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also the first case described of bilateral sixth cranial 
nerve palsy and DCA. 
 
Case report 
A 14-year-old Caucasian male resident in 
Kinshasa, Democratic Republic of the Congo, was 
referred to our infectious diseases clinic with a five-
day history of fever, chills, sweating, malaise and 
watery diarrhoea. Splenomegaly was the only 
abnormal finding upon physical examination. He had 
a past history of one episode P. falciparum malaria. 
Peripheral blood analysis showed anemia 
(hemoglobin: 9.7 g/dL), leukopenia (3,900/mL), and 
thrombocytopenia (12,000/mL). C-reactive protein 
(CRP) was 20.21 mg/L. A blood smear revealed the 
presence of P. falciparum ring forms with a 
parasitemia level of 7%. Rapid antigenic tests were 
positive for P. falciparum. 
Intravenous quinine sulfate plus doxycycline 
were administered over seven days. Intravenous 
ceftriaxone was started and maintained until negative 
blood culture results were available, because enteric 
fever (Salmonella typhi and Salmonella paratyphi) 
can be acquired in developing countries worldwide 
and may coexist with malaria but also bacteremia 
complicating severe malaria is not uncommon in 
infants and children and may cause any patient's 
clinical status to deteriorate abruptly. The next day, 
excessive sleepiness and diminished talkativeness 
was observed. 
Peripheral blood analysis showed hyponatremia 
(124.6 mmol/L), hypoalbuminemia (2.1 g/dL), 
elevated lactate dehydrogenase (1043 U/L), alanine 
transaminase and, aspartate aminotransferase (82 
U/L) values; arterial hypoxemia, hyperlactatemia 
(5.46 mmol/L), metabolic acidosis; blood level 
parasitemia of 14% and anemia (Hb-6.5 mg/dL).  
He was transferred to the intensive care unit and 
transfused with packed red blood cells. On day 3, a 
bilateral sixth cranial nerve palsy was diagnosed. On 
day 4, parasitemia was negative; HRP-2 based rapid 
diagnostic test was positive. Electroencephalogram 
(EEG) showed the presence of bilateral slow-wave 
activity consistent with diffuse encephalopathy. Brain 
magnetic resonance imaging (MRI) and computed 
tomography (CT) scans showed no alterations. On 
day 9, he was discharged maintaining symptoms of 
double vision and signs of bilateral sixth cranial 
nerve palsy. 
Twelve days later, he was readmitted because of 
sudden onset of fever (39.8ºC), somnolence, word-
finding difficulty and postural tremor. He was easily 
rousable, conscious and oriented, and no meningeal 
signs were apparent; neurological assessment showed 
a truncal ataxia. He had one episode of generalized 
tonic-clonic seizure followed by a postictal state in 
the nursery. Blood analysis showed a CRP of 1.21 
mg/L and thrombocytopenia (121,000/mL). 
Cerebrospinal fluid (CSF) analysis showed elevated 
protein content (44 mg/dL) and a pleocytosis of 92 
mononuclear cells. Intravenous quinine and 
doxycycline were started and maintained for three 
days.  
A provisional diagnosis of meningoencephalitis 
was considered. Meningoencephalitis due to Listeria 
monocytogenes may mimic herpes encephalitis. 
However, brain imaging, electroencephalogram, and 
polymerase chain reaction (PCR) results made a viral 
hypothesis less probable. Empiric treatment with 
ampicillin was started and maintained over 10 days, 
until CSF culture results were reported negative. 
Repeated peripheral blood smears were negative 
for ring forms of Plasmodium sp. However, HRP-2 
test positivity and thrombocytopenia was maintained 
until day seven after readmission. Brain tomography 
and MRI were normal. Electroencephalogram (EEG) 
showed slow-wave activity consistent with diffuse 
encephalopathy. PCR for herpes simplex viruses, 
varicella zoster virus, human herpesvirus type 6, and 
enterovirus were negative in the CSF. Serology for 
arboviruses, enteroviruses, syphilis, leptospirosis, Q-
fever, toxoplasmosis, mycoplasma, cytomegalovirus, 
Epstein-Barr virus and HIV-1/2 were negative. 
Autoimmunity studies were negative. EEG alterations 
normalized and cerebellar ataxia disappeared after 
two weeks. The patient was discharged and was sent 
home. 
Two months later, a complete recovery from the 
bilateral sixth cranial nerve palsy was observed. 
 
Discussion 
Cerebellar syndromes have been reported in both 
complicated and uncomplicated P. falciparum 
malaria and rarely after P. vivax infection [10,11]. 
Acute cerebellar ataxia is encountered during the 
recovery period after cerebral malaria and DCA 
occurs after uncomplicated malaria; the occurrence is 
estimated to be 0.25% [2]. Most of the cases (97%) 
were associated with severe malaria with a high 
(median, 16%) parasitemia. Time from the clearance 
of parasitemia to the first neurological symptom 
ranged from four to 15 days, while the median 
duration of the disease varied from 2.5 to 13 days [2]. 
The most common signs and symptoms are impaired 
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consciousness (77%), confusion (66%), fever (50%), 
generalized seizure (33%), aphasia (28%), tremor 
(23%), psychosis (17%) and myoclonus (11%), 
headache (8%), weakness (6%), catatonia (6%) and 
ataxia (6%) [3]. 
The pathogenic mechanisms associated with 
PMNS are not fully understood. Their rapid 
resolution makes a structural lesion unlikely and the 
clearance of parasitemia before symptoms onset 
make a cytoadherence mechanism less probable. 
EEG in our patient revealed diffuse background 
slowing, suggesting mild to severe encephalopathy. 
Brain MRI scans often show increased signal uptake 
in various regions. Brain CT scans are normal [3]. 
CSF analysis is abnormal in most patients with 
lymphocytic pleocytosis (50%) and elevated protein 
content (70%). Mild pleocytosis and increased 
protein content can also be the result of seizures; 
therefore, other causes of encephalopathy must be 
excluded [12]. CSF lymphocytic pleocytosis and 
elevated protein levels may support an immune 
mechanism at least in those patients without seizures. 
However, trigger factors for an immune mechanism 
after the successful treatment of an episode of malaria 
are currently unknown. No link between PMNS and 
different new strains of P. falciparum has been 
established so far. 
Our patient had two simultaneous neurological 
manifestations: the bilateral sixth cranial nerve palsy 
sequel to severe infection, and DCA, a PMNS. These 
manifestations seem to be the result of the interplay 
involving different factors from the host (immunity, 
platelets and vascular endothelium) and from the 
parasite (Plasmodium adhesion molecules) leading to 
a state of inflammation either in the presence of 
infected erythrocytes (cranial nerve palsy) or in their 
absence (DCA). 
The mechanism of immunity is still unclear. 
CD4+ T-cells play a central role in the immune 
response to malaria. They are required to help B-cells 
to produce the antibody that is essential for parasite 
clearance [13]. Acquired protection from malaria 
following natural exposure to P. falciparum parasites 
is mediated by IgG. Parasite-encoded, clonally 
variant surface antigens (VSA) are the main targets of 
protective IgG. They are organized into families, and 
the best-known antigen is P. falciparum erythrocyte 
membrane protein 1 (PfEMP1), which is located in 
the knob structures on the infected erythrocyte 
surface [14]. VSA mediate the adhesion of the mature 
developmental stage (trophozoites and schizonts) 
infected erythrocytes to different receptors present in 
the host vasculature. Each parasite genome has 
multiple VSA-encoding genes for protein variants 
with different antigenic and adhesive properties. VSA 
diversity appears to be finite, as immune sera from 
African adults can recognize infected erythrocytes 
from different continents [14,15]. VSA associated 
with severe malaria are frequently and strongly 
recognized by antibodies in individuals with no or 
little pre-existing immunity. VSA associated with 
uncomplicated malaria and asymptomatic infection in 
semi-immune people are those that are rarely and 
poorly recognized by the immune system [14,15]. 
In areas of stable transmission, clinical immunity 
to mild malaria is acquired slowly, and it is not 
usually effective until early adolescence. Life-
threatening disease is restricted to a much younger 
age group, indicating that resistance to severe 
infection is acquired more quickly [16]. This concept 
suggests that all the first P. falciparum infections 
should be the most severe. 
The case presented is an argument against this 
concept because our patient had a previous episode of 
uncomplicated malaria in 1997 when he had no pre-
existing immunity followed by the more severe and 
complicated infection we describe here. We believe 
that our patient was probably infected by a local 
strain for which he had no previous VSA-specific 
antibodies, either because immunity was lost by lack 
of stimulation since 1997 or because he became 
infected with a different new strain. In both cases the 
parasite took advantage of a “hole” in the immune 
repertoire of the patient that was closed by the 
ensuing disease.  However, there is a lack of evidence 
for antibody mediation in DCA [17].  
Overproduction of cytokines is associated with 
the activation of the vascular endothelium, a key 
component of cerebral malaria but not the only one 
[18]. The inflammatory cytokines (IL-1, IL-2, IFN-ϒ, 
and TNF-α) are all required for the development of 
experimental severe malaria (ESM). A marked 
elevation of serum TNF-α, IL-6, and IL-2 was 
demonstrated in DCA [19,20]. CD4+ T-cell 
activation leads to the production of pro-
inflammatory cytokines, which up-regulate a variety 
of macrophage functions, one of which is the release 
of TNF-α in response to malaria antigens [21]. Also, 
sequestered leucocytes release TNF-α, leading to the 
amplification of a cytotoxic effect on endothelial 
cells, vascular wall damage and hemorrhagic 
necrosis. A clear role for TNF-α has been shown in 
parasite killing. At physiological concentrations, 
recombinant TNF-α is antiparasitic, synergizing with 
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IFN-ϒ to induce production of nitric oxide and other 
toxic radicals [22]. Differences in resistance and 
susceptibility to ESM in different strains of mice 
correlate with the development of inflammatory 
versus anti-inflammatory cytokines [20]. 
These data suggest that pre-existing immunity 
can modulate the severity of the disease. Our patient 
could have had some immunity to P. falciparum 
because he was living in a country endemic for 
malaria and he had had a previous infection, which 
probably accounted for his being partly protected 
against the development of cerebral malaria. 
Our patient had elevated CRP during the acute 
phase of malaria and during DCA with values of 
20.21 mg/dL and 1.21 mg/dL, respectively. These 
data suggest that different levels of inflammation 
occurred during both episodes. The severity of the 
clinical manifestations correlated with CRP and 
thrombocytopenia values. Thrombocytopenia is 
common in all forms of malaria. Platelet-mediated 
red blood cell agglutination has been associated with 
severe malaria and platelet binding to endothelial 
cells was associated with increased cell permeability 
[23]. CD36, a platelet receptor for infected 
erythrocytes, is also present in brain endothelium and 
may play a role in platelet activation. However, the 
exact mechanism for thrombocytopenia is not known 
[24].  
Our case presented severe thrombocytopenia 
during acute malaria and during DCA with the 
simultaneous persistence of HRP-2 antigen until 
recovery from DCA. Histidine-rich protein 2 (HRP-
2) is a water-soluble protein produced by asexual 
forms and young gametocytes of P. falciparum. 
HRP-2 based rapid diagnostic tests can stay positive 
for more than five weeks after successful treatment 
because of prolonged persistence of HRP-2 antigen in 
the circulation after parasite death and/or because of 
longer but limited persistence of immature 
gametocytes in the blood after successful therapy 
[25]. It is not known whether persistent HRP-2 
antigenemia or the gametocytes have any role in the 
development of DCA. 
Our patient was treated with blood-stage 
schizonticide drugs which are effective against 
multidrug-resistant parasites but do not eliminate 
gametocytes. However, PMNS was described after 
treatment with artemisins, which are gametocytocide 
drugs, suggesting that a clean-up mechanism of 
Plasmodium antigens could be involved. A synergic 
effect was found between mefloquine treatment and 
disease severity in inducing PMNS [2]. However, 
mefloquine is not the only risk factor. PMNS may 
occur in patients that had not received the drug and 
also may follow uncomplicated P. falciparum malaria 
[9]. 
To conclude, we describe a case of severe P. 
falciparum malaria with high-level parasitemia and 
severe thrombocytopenia, complicated by bilateral 
sixth cranial nerve palsy, and followed by delayed 
cerebellar ataxia during the recovery phase. 
Pathogenic mechanisms and associated clinical 
syndromes in P. falciparum malaria may result from 
the complex interplay between host-related factors in 
which previous immunity could be an important 
aspect. Also, parasite related factors could be 
involved, modulating the intensity of the 
immunological mechanisms and the degree of the 
associated brain damage. 
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